Elfabrio logo Elfabrio logo Elfabrio logo

For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.

Visit website

In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.

Insert text here...

Ferriprox Logo Ferriprox Logo Ferriprox Logo

For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.

Visit website

In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. If you have any questions about this product or your health, please contact your physician.

Disclaimer: Ferriprox 1000 mg tablets only available in The Netherlands.

Insert text here...

Procysbi Procysbi Procysbi

For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.

Visit website

In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.

Insert text here...

Lamzede Velmanase Alfa Lamzede Velmanase Alfa Lamzede Velmanase Alfa

For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.

Visit website

In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.

Raxone Raxone Raxone

For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.

Visit website

In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.

Learn More about Chiesi Global Rare Diseases - Benelux

In the News

In
the News

Stay up to date with the latest news and happenings at Chiesi Global Rare Diseases - Benelux.

Read more

Pipeline

Explore rare disease therapies under development.

Read More

About Us

About 
Us

Learn more about who we are and why Chiesi Global Rare Disease - Benelux cares about improving the lives of people with rare diseases.

Read More

For Healthcare Professionals

For Healthcare
Professionals

From research to results, see how we’re committed to helping you help your patients.

Read More